SEC Form 5 · accession 0000899243-17-004068
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Charles J Homcy
Director
Period of report
Dec 31, 2016
Accepted (ET)
Feb 14, 2017 · 7:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 3, 2016 | J | 14,611 | $0.00 | A | 227,296 | D | |
| Common StockF2 | Dec 16, 2016 | J | 10,432 | $0.00 | A | 237,728 | D | |
| Common Stock | holding | — | — | — | 1,600 | I | Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 14,611 shares received by the Reporting Person in a distribution-in-kind by Third Rock Ventures II, L.P. ("TRV II") on November 3, 2016, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended, as reported on Form 4s filed by the Reporting Person on November 7, 2016 and November 16, 2016. This report is being filed with respect to this transaction solely to correct the total number of shares held by the Reporting Person immediately following the transaction.
- F2Includes 10,432 shares received by the Reporting Person in a distribution-in-kind by TRV II on December 16, 2016, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended.